Published on 09/12/2025

Identity Testing: Sequencing, Proteomics, and Flow Cytometry

In the field of pharmaceutical validation, identity testing is a critical process, especially when dealing with biologics, Advanced Therapy Medicinal Products (ATMPs), and viral safety validation. This step-by-step tutorial will provide a comprehensive overview of three primary methodologies: sequencing, proteomics, and flow cytometry. We will discuss their significance in ensuring potency and identity for critical quality attributes (CQAs), with a specific focus on viral clearance validation, spiking studies, and the integration of closed/single-use systems.

Understanding the Need for Identity Testing in Biologics

Identity testing is essential for confirming the genuineness and specificity of biological products. Regulatory bodies such as the FDA, EMA, and MHRA necessitate rigorous identity testing to meet current Good Manufacturing Practice (cGMP) guidelines. The primary objectives of identity testing include:

• Confirmation of Biological Identity: To ensure that the intended product is actually being produced and utilized.
• Regulatory Compliance: To meet the regulatory requirements for potency and identity before approvals.
• Risk Management: To mitigate risks associated with product misidentification and contamination.

Viral clearance validation, spiking studies, and the chain of identity custody are crucial components of a comprehensive identity testing strategy. By following these steps, pharmaceutical companies can ensure that they meet regulatory expectations.

Step 1: Preparing a Validation Plan for Identity Testing

The initial step in the identity testing process is the development of a robust validation plan. This plan should outline the scope, objectives, and methodologies to be employed. Key components of the validation plan include:

• Objectives: Clearly define what the identity testing aims to achieve, such as the specific CQAs that need to be verified.
• Method Selection: Choose appropriate methodologies, such as sequencing, proteomics, and flow cytometry, based on the product characteristics and regulatory requirements.
• Resources Required: Identify the necessary equipment, reagents, and personnel qualifications needed for the testing.

The validation plan serves as the foundation for all subsequent activities, ensuring that all aspects of the testing process are adequately addressed. A well-structured plan will enhance the credibility of test results, thus facilitating smooth regulatory submissions.

Step 2: Implementing Sequencing Techniques

Sequencing techniques are pivotal for establishing the identity of biologics, particularly in the context of nucleic acids and protein characterization. Techniques such as Next-Generation Sequencing (NGS) are increasingly being used due to their ability to produce high-density data that can be critical for identity verification. When employing sequencing techniques, consider the following steps:

• Sample Collection: Ensure that the samples collected are representative and handled under stringent aseptic conditions to prevent contamination.
• Library Preparation: Construct the sequencing library by preparing the DNA or RNA samples, which may include fragmentation, adapter ligation, and amplification.
• Sequencing: Carry out the sequencing process (e.g., NGS, Sanger sequencing) and obtain data for analysis.
• Data Analysis: Analyze the sequencing data using bioinformatics tools to confirm that the sequences match those expected for the biologic in question.

Method validation is crucial to ensure the reliability of sequencing results. Use established guidelines, including ICH Q5A(R2), for guidance on viral clearance and identity testing methodologies.

Step 3: Utilizing Proteomics in Identity Testing

Proteomics involves the large-scale study of proteins, which are vital to understanding the identity and function of biological products. This method complements sequencing by providing information about the structure and modifications of proteins involved in the product. Key steps in implementing proteomics include:

• Sample Preparation: Optimize sample extraction techniques to capture the protein profile accurately while avoiding degradation or modification.
• Separation Techniques: Employ methods such as 2D gel electrophoresis or chromatography to separate the proteins for analysis.
• Mass Spectrometry: Utilize mass spectrometry to identify and quantify proteins, focusing on their molecular weight and unique mass signatures.
• Bioinformatics Analysis: Apply bioinformatics tools to analyze the mass spectrometry data, enabling the identification of specific proteins that confirm product identity.

The integration of proteomics into the identity testing framework not only enhances the overall understanding of product integrity but also aligns with the evolving regulatory requirements regarding product characterization.

Step 4: Implementing Flow Cytometry for Cell-Based Products

Flow cytometry is a powerful technique commonly used for identity testing of cell-based products due to its ability to analyze multiple parameters in single cells simultaneously. Particularly in ATMPs, flow cytometry is integral for assessing cell identity, viability, and functionality. Follow these steps for an effective flow cytometry approach:

• Sample Preparation: Collect and prepare the cell samples, ensuring to minimize any stress to the cells that could affect their viability.
• Staining: Use appropriate fluorescent markers to label the cells based on specific parameters such as surface markers or intracellular signaling molecules.
• Analysis: Operate the flow cytometer and collect data on cell populations, analyzing the results to confirm cell identity by matching expected profiles.
• Validation: Validate the flow cytometry method by evaluating its specificity, sensitivity, and reproducibility according to established QA protocols.

The incorporation of flow cytometry into identity testing ensures that regulatory mandates for biologics, especially those that involve complex CQAs, are met effectively.

Step 5: Conducting Viral Clearance Validation

One of the most pivotal aspects of biologics validation is ensuring that the products are free from viral contamination. Viral clearance validation helps to establish the effectiveness of the manufacturing process in removing or inactivating viruses. Key steps in conducting viral clearance validation include:

• Risk Assessment: Conduct an initial risk assessment to identify potential viral contaminants based on raw materials, manufacturing processes, and supplier assessments.
• Spiking Studies: Perform spiking studies where known viruses are introduced into the process, and subsequent analysis confirms their removal/inactivation.
• Statistical Modeling: Apply statistical models to assess viral clearance data, taking into account variations in batch production and processing methods.
• Documentation: Maintain thorough documentation of the validation protocol, results, and conclusions for future regulatory inspections.

According to guidance from guidelines such as WHO, viral clearance studies must be aligned with the specific characteristics and risks associated with the biopharmaceutical products being developed.

Step 6: Chain of Identity Custody

Maintaining a robust Chain of Identity Custody (CoIC) is critical in ensuring that the identity of biological materials is preserved throughout the lifecycle of product development. To effectively manage CoIC, companies should implement the following practices:

• Traceability Systems: Establish detailed records that track materials from their source through manufacturing, testing, and distribution.
• Audit Trails: Implement electronic systems that create audit trails documenting all handling, testing, and analytical processes.
• Staff Training: Provide ongoing training to staff regarding the importance of maintaining CoIC and the procedures necessary for accurate turnover of materials.

Ensuring a strong CoIC system reduces the risk of mix-ups or contamination and strengthens overall product integrity.

Step 7: Tailoring the Process Validation Protocols

Process validation is critical in the assessment of identity testing within the context of biologics. Tailoring the process validation protocols to meet the specific needs of ATMPs is essential due to their unique characteristics. The following outlines a structured approach to process validation:

• Prototype Development: Develop prototypes of the manufacturing processes to evaluate their performance in achieving the required CQAs.
• Performance Qualification (PQ): Conduct PQ to validate that the entire manufacturing process consistently produces a product meeting specifications.
• Continued Process Verification (CPV): Implement CPV strategies to monitor the ongoing performance of the process throughout its lifecycle.
• Adjustments and Optimization: Be prepared to make adjustments based on data gathered during validation to ensure continued compliance with regulatory expectations.

Process validation tailored towards the unique demands of ATMPs ensures that the identity and potency CQAs remain intact during the manufacturing process.

Conclusion: Navigating to Successful Identity Testing in Biologics

Identity testing is a multifaceted process that plays a key role in ensuring the safety and effectiveness of biologics and ATMPs. By implementing rigorous methodologies including sequencing, proteomics, and flow cytometry, pharmaceutical professionals can uphold regulatory standards while ensuring product integrity. Additionally, the incorporation of viral clearance validation, robust chain of identity custody, and tailored process validation ensure compliance with regulations set forth by bodies like the FDA, EMA, and MHRA.

By adhering to these guidelines and protocols, companies can enhance their product development processes, thereby contributing to improved patient safety and therapeutic efficacy.